Andrew Baum
Stock Analyst at Citigroup
(2.88)
# 1,497
Out of 4,818 analysts
62
Total ratings
69.77%
Success rate
11.92%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $78.69 | +46.15% | 13 | Feb 5, 2025 | |
| PFE Pfizer | Maintains: Neutral | $30 → $29 | $22.36 | +29.72% | 10 | Jan 28, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $65 | $48.50 | +34.01% | 11 | Jan 28, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $31.69 | +26.22% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $176.95 | +21.50% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $829.24 | +7.93% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $8.36 | +19.62% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $37.03 | - | 2 | Jul 5, 2017 |
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $78.69
Upside: +46.15%
Pfizer
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $22.36
Upside: +29.72%
Bristol-Myers Squibb Company
Jan 28, 2025
Maintains: Neutral
Price Target: $60 → $65
Current: $48.50
Upside: +34.01%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $31.69
Upside: +26.22%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $176.95
Upside: +21.50%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $829.24
Upside: +7.93%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $8.36
Upside: +19.62%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $37.03
Upside: -